

Dated: June 15, 2022

To,  
The Manager,  
Dept. of Corporate Services,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400001

Dear Sir/Madam,

**Subject** : Disclosure of Related Party Transactions for the half-year ended 31.03.2022  
**Reference** : Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015  
**Scrip Code** : 511509

With reference to the above cited subject, please find enclosed the details of Related Party Transactions for the half-year period from 01.10.2021 to 31.03.2022 in the format as specified under Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular bearing reference no. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021.

Kindly take the above information on record.

Thanking You,

Yours Truly

For Vivo Bio Tech Limited



**Jyotika Aasat**  
Company Secretary



Encl.: As above

S.No	Details of the party listed into the transaction		Details of the counterparty		Type of related party transaction	Value of the transaction approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction when such transaction was undertaken.		Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period.		
	Name	PAN	Name	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance (As on October 01, 2021)	Closing balance (As on March 31, 2022)	Nature (loan/advance/inter-corporate deposit/investment)	Tenure	Interest Rate (%)
1	Vivo Bio Tech Limited		Donakant Consulting Services Private Limited	Subsidiary	Investment in Equity	-	-	100,000	100,000			
2	Vivo Bio Tech Limited		Surajic Life Consultancy Private Limited	Subsidiary	Investment in Equity	-	-	100,000	100,000			
3	Vivo Bio Tech Limited		Vivo Bio Discovery Services Private Limited	Subsidiary	Investment in Equity	-	-	100,000	100,000			
4	Vivo Bio Tech Limited		Vivo Bio Labs Private Limited	Subsidiary	Investment in Equity	-	-	100,000	100,000			
5	Vivo Bio Tech Limited		Vitrinchi Limited	Common Promoter	Receivable of Services	43,200,000	43,200,000	-	43,200,000			
6	Vivo Bio Tech Limited		Donakant Consulting Services Private Limited	Subsidiary	Loans & Advances	500,000	500,000	9,625,120	10,125,120			
7	Vivo Bio Tech Limited		Surajic Life Consultancy Private Limited	Subsidiary	Loans & Advances	500,000	500,000	2,912,250	3,412,250			
8	Vivo Bio Tech Limited		Vivo Bio Discovery Services Private Limited	Subsidiary	Loans & Advances	500,000	500,000	106,000	606,000			
9	Vivo Bio Tech Limited		Vivo Bio Labs Private Limited	Subsidiary	Loans & Advances	500,000	500,000	1,377,900	1,877,900			
10	Vivo Bio Tech Limited		M Kalyan Ram	Whistleblower Director	Remuneration	851,204	430,622	-	-			
11	Vivo Bio Tech Limited		K Sri Kalyan	Whistleblower Director & CFO	Remuneration	-	3,70,000	-	-			
12	Vivo Bio Tech Limited		K T V Kalahar	Whistleblower Director & CFO	Remuneration	664,370	293,698	-	-			
13	Vivo Bio Tech Limited		A K	Company Secretary	Remuneration	901,204	470,622	-	-			
14	Vivo Bio Tech Limited		***Sankaranarayanan Alangudi	Non Executive Director (upto 05.01.2022)	Sitting Fees	-	20,000	-	-			
15	Vivo Bio Tech Limited		***Sankaranarayanan Alangudi	Whistleblower Director (w.e.f. 06.01.2022)	Remuneration	-	286,627	-	-			
16	Vivo Bio Tech Limited		Shibaansud Nayak Karupadi	Non Executive Director	Sitting Fees	-	40,000	-	-			
17	Vivo Bio Tech Limited		Sunder Kanaparthi	Independent Director	Sitting Fees	-	85,000	-	-			
18	Vivo Bio Tech Limited		Harsharan Ravindran	Independent Director	Sitting Fees	-	55,000	-	-			
19	Vivo Bio Tech Limited		Vishwanath Kompella	Advisor and Common Promoter	Remuneration	15,000,000	9,000,000	-	-			
20	Vivo Bio Tech Limited		Madhavi Latha	Advisor and Common Promoter	Remuneration	9,000,000	9,000,000	-	-			
21	Vivo Bio Tech Limited		Vitrinchi Health Care Private Limited	Quarantor/Collateral Golem	Remuneration	-	-	695,000,000	695,000,000			
22	Vivo Bio Tech Limited			Common Promoter		-	-	-	-			
												64,946,549

Notes:  
 \*\*Mr. K S V Kalyan was appointed as the Whistleblower Director & CFO of the Company w.e.f. November 03, 2021, vide resolution passed by the shareholders through postal ballot on January 06, 2022.  
 \*\*\*Mr. K T V Kalahar ceased to be the Whistleblower Director & CFO of the Company w.e.f. November 03, 2021, vide resolution passed by the shareholders through postal ballot on January 06, 2022.  
 \*\*\*Mr. Sankaranarayanan Alangudi who was initially appointed as the Non-Executive Director of the Company, was appointed as Whistleblower Director of the Company w.e.f. January 06, 2022, vide resolution passed by the shareholders through postal ballot on January 06, 2022.

